Assembly Historical Balance Sheet
ASMB Stock | USD 16.83 1.63 10.72% |
Trend analysis of Assembly Biosciences balance sheet accounts such as Short Long Term Debt Total of 2.2 M, Other Current Liabilities of 5 M or Total Current Liabilities of 41.2 M provides information on Assembly Biosciences' total assets, liabilities, and equity, which is the actual value of Assembly Biosciences to its prevalent stockholders. By breaking down trends over time using Assembly Biosciences balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Assembly Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Assembly Biosciences is a good buy for the upcoming year.
Assembly Biosciences Inventory |
|
Assembly |
About Assembly Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Assembly Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Assembly Biosciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Assembly Biosciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Assembly currently owns. An asset can also be divided into two categories, current and non-current.
Assembly Biosciences Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Assembly Biosciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Assembly Biosciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Assembly Biosciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Assembly Biosciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Intangible Assets
Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.Most accounts from Assembly Biosciences' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Assembly Biosciences current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assembly Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.At present, Assembly Biosciences' Total Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Property Plant And Equipment Net is expected to grow to about 3 M, whereas Total Assets are forecasted to decline to about 130.2 M.
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 6.5M | 3.5M | 2.3M | 2.2M | Total Assets | 191.1M | 101.8M | 136.8M | 130.2M |
Assembly Biosciences balance sheet Correlations
Click cells to compare fundamentals
Assembly Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Assembly Biosciences balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 339.9M | 283.3M | 191.1M | 101.8M | 136.8M | 130.2M | |
Other Current Liab | 13.1M | 13.0M | 7.1M | 7.1M | 6.6M | 5.0M | |
Total Current Liabilities | 24.4M | 24.4M | 16.1M | 16.3M | 39.2M | 41.2M | |
Total Stockholder Equity | 273.2M | 240.6M | 168.9M | 82.7M | 41.1M | 39.0M | |
Property Plant And Equipment Net | 13.8M | 10.7M | 7.2M | 3.9M | 2.7M | 3.0M | |
Net Debt | (34.5M) | (49.3M) | (39.2M) | (49.0M) | (17.5M) | (18.4M) | |
Retained Earnings | (439.4M) | (501.6M) | (631.4M) | (724.5M) | (785.7M) | (746.5M) | |
Accounts Payable | 1.7M | 4.6M | 2.7M | 2.5M | 461K | 438.0K | |
Cash | 46.7M | 59.4M | 45.6M | 52.4M | 19.8M | 36.5M | |
Non Current Assets Total | 57.1M | 58.8M | 36.9M | 4.8M | 3.0M | 2.9M | |
Non Currrent Assets Other | 1.7M | 6.4M | 1.7M | 78K | (334K) | (317.3K) | |
Other Assets | 1.7M | 6.4M | 1.7M | (646.0K) | (742.9K) | (705.8K) | |
Cash And Short Term Investments | 274.0M | 216.4M | 146.6M | 91.6M | 130.2M | 99.4M | |
Common Stock Total Equity | 25K | 32K | 34K | 49K | 56.4K | 59.2K | |
Common Stock Shares Outstanding | 2.2M | 39.7M | 46.8M | 4.0M | 4.6M | 4.3M | |
Liabilities And Stockholders Equity | 339.9M | 283.3M | 191.1M | 101.8M | 136.8M | 130.2M | |
Non Current Liabilities Total | 42.3M | 18.2M | 6.1M | 2.8M | 57.1M | 62.5M | |
Other Current Assets | 5.4M | 13.7M | 14.5M | 4.4M | 6.7M | 3.4M | |
Other Stockholder Equity | 712.8M | 742.4M | 800.7M | 807.9M | 826.9M | 868.3M | |
Total Liab | 66.7M | 42.7M | 22.1M | 19.1M | 95.7M | 100.5M | |
Property Plant And Equipment Gross | 13.8M | 10.7M | 7.2M | 3.9M | 2.9M | 3.0M | |
Total Current Assets | 282.8M | 224.5M | 154.2M | 97.0M | 133.8M | 102.4M | |
Accumulated Other Comprehensive Income | (201K) | (270K) | (419K) | (803K) | (81K) | (85.1K) | |
Common Stock | 32K | 34K | 48K | 49K | 5K | 4.8K | |
Property Plant Equipment | 1.8M | 1.6M | 7.2M | 743K | 854.5K | 1.0M | |
Net Tangible Assets | 231.6M | 198.9M | 168.9M | 82.7M | 95.1M | 107.5M | |
Retained Earnings Total Equity | (341.8M) | (439.4M) | (501.6M) | (724.5M) | (652.1M) | (619.5M) | |
Short Term Investments | 227.3M | 157.0M | 101M | 39.2M | 110.4M | 77.4M | |
Capital Surpluse | 552.8M | 712.8M | 742.4M | 807.9M | 929.1M | 975.6M | |
Other Liab | 38.9M | 33.2M | 11.5M | 2.7M | 2.5M | 2.3M | |
Current Deferred Revenue | 5.1M | 6.4M | 9.0M | 2.7M | 30.9M | 32.5M | |
Net Receivables | 3.4M | 1.2M | 336K | 944K | 43K | 40.9K | |
Net Invested Capital | 273.2M | 240.6M | 168.9M | 82.7M | 41.1M | 39.0M | |
Net Working Capital | 258.3M | 200.1M | 138.1M | 80.7M | 94.6M | 124.0M | |
Capital Stock | 32K | 34K | 48K | 49K | 5K | 4.8K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Assembly Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Assembly Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Assembly Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Assembly Biosciences Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assembly Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Assembly Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.89) | Revenue Per Share 4.125 | Quarterly Revenue Growth (1.00) | Return On Assets (0.35) | Return On Equity (1.02) |
The market value of Assembly Biosciences is measured differently than its book value, which is the value of Assembly that is recorded on the company's balance sheet. Investors also form their own opinion of Assembly Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Assembly Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Assembly Biosciences' market value can be influenced by many factors that don't directly affect Assembly Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Assembly Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Assembly Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.